AURKA and renal cell carcinoma: Although half the nodules in bexarotene-treated animals did not progress to fulminant tumors, the efficacy of bexarotene in modulating AURKA remained unaltered in tumors from these xenografts, highlighting the potential of exploring bexarotene as an intervention strategy in the clinic to manage renal cystogenesis associated with VHL disease and RCC.